[home]
[thesaurus]
Click Here to return To Results
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
See this aricle in Pubmed
Article Abstract
Alemtuzumab provides durable efficacy through 5 years in patients with an inadequate response to prior therapy in the absence of continuous treatment.
Related Tags
(click to filter results - removes previous filter)
alemtuzumab
brain atrophy
efficacy
immunomodulation
monoclonal antibodies
MRI,abnormal
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
safety
treatment of neurologic disorder
Click Here to return To Results